RBL2 and esophageal squamous cell carcinoma: SMAD4 is enriched in adherens junction and cell cycle pathways and has been found to have a potential predictive value for esophageal squamous cell carcinoma in patients receiving neoadjuvant chemoradiotherapy (39) RBL2 and CDKN1B are enhanced in cell cycle pathways.